Saturday 23 Sep, 2023 05:21 AM
Site map | Locate Us | Login
   Dhampur Sugar CEO Anant Pande resigns    KPI Green jumps after bagging order for 145.20 MW hybrid power project    EKI Energy Services Ltd leads losers in 'A' group    Lupin buys five brands from Italy-based Menarini for Rs 101 cr    STL Global Ltd leads losers in 'B' group    Volumes jump at Carborundum Universal Ltd counter    Power shares edge lower    Consumer Durables stocks slide    Healthcare shares fall    CRISIL upgrades ratings of HPL Electric to 'A-/A2+' with 'stable' outlook    National Aluminium Company Ltd slips for fifth straight session    New Delhi Television Ltd down for fifth straight session    Godrej Consumer Products Ltd drops for fifth straight session    Jindal Stainless Ltd eases for fifth straight session    Divis Laboratories Ltd slips for fifth straight session 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Aarti Drugs jumps on buzz DGTR recommends anti-dumping duty on Ofloxacin
17-Aug-22   09:57 Hrs IST

Ofloxacin is a quinolone antibiotic useful for the treatment of a number of bacterial infections.

Aarti Drugs had earlier filed an application for anti-dumping duty on Ofloxacin and its intermediates imported from China.

Following the application, an anti-dumping investigation concerning imports of Ofloxacin and its intermediates originating in or exported from China PR was initiated on 17 September 2021 under the Customs Tariff (Identification, Assessment and Collection of Anti-dumping duty on Dumped Articles and for Determination of Injury) Rules, 1995 (AD Rules).

DGTR has reportedly completed investigation on the application of Aarti Drugs and has recommended continuation of anti-dumping duty on Ofloxacin and its intermediates imported from China.

Aarti Drugs is primarily involved in manufacturing and marketing of active pharmaceutical ingredients (API), pharma intermediates and specialty chemicals.

On a consolidated basis, net profit of Aarti Drugs declined 28.72% to Rs 34.79 crore on 7.24% rise in net sales to Rs 621.96 crore in Q1 June 2022 over Q1 June 2021.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 28308767
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd